Brussels, 22 Jul 2005
Nanotechnology and the health of the European Citizen in 2020 Special media programme on new developments in European nanotechnology research and the future of healthcare on the occasion of EuroNanoForum 2005.
5-7 September 2005
EuroNanoForum 2005 Conference and Expo
The Edinburgh Exhibition and Conference Centre, Edinburgh,
Scotland.
For leading EU and international nanotechnology experts, nanotech industry CEOs, senior policymakers from the EU, USA, China and Japan
EURONANOFORUM 2005: EUROPE'S FLAGSHIP EVENT ON NANOTECHNOLOGY
ÁñÁ«ÊÓƵ
Organized by the Institute of Nanotechnology, with the support of the European Commission, EuroNanoForum 2005 is one of the world's most important Conference and Expo in the field of nanotechnology research and industrial applications. This year, this flagship European event will specifically focus on healthcare application of nanotechnologies – and acknowledged area of European strength and interest. Europe is at the forefront of scientific advances in this field. In particular, EU researchers, developers and scientists lead the way in the development of new procedures, devices and applications in the field of healthcare. Heralding a revolution in healthcare, nanotechnology research provides molecular-sized solutions to some of the most pressing modern medical problems.
EU AT THE FOREFRONT OF NANOTECHNOLOGY – AND HEALTH RESEARCH
ÁñÁ«ÊÓƵ
Nanotechnology is a key area of European Research, and one of the priorities of the 6th and 7th Framework programmes. In the recently published European Nanotechnology Action Plan, the EU has announced the ways in which it intends to keep Europe at the forefront of the fast-moving field of nanotechnology in a safe and responsible way.
Applications of nanotechnology – activities at the level of atoms and molecules – are bringing a range of benefits including more effective ways of delivering drugs to treat diseases, faster computer processors and more efficient solar cells. The Action Plan proposes measures to be taken at national and EU level, including boosting funding for nanotechnology, developing world-class competitive infrastructure, creating favourable conditions for EU industry to turn research into useful products and services, addressing public health, safety and environmental risks, promoting inter-disciplinary education & training, and strengthening international dialogue on key issues of mutual concerns.
THE CONFERENCE
EuroNanoForum2005 is the conference to attend in 2005 if you want:
- An understanding of advanced medical technologies that have numerous applications in a variety
of industries including defence, textiles, ICT and many others.
- Insights into applications for the developing world and ageing population.
- Indicators of new business opportunities and threats.
- To be at the forefront of the debate into ethics and toxicology issues surrounding nanotechnology
The event will gather over 1500 participants from all over the world, with over 90 leading speakers from 25 countries. During the Conference, participants will be able to discover the latest developments in tissue engineering, drug delivery and pharmaceutical development, nano and congenital/ degenerative disease, nanoimaging, affordable cures, implants and devices, new nano techniques and tools, risk assessment and ethical responsibilities, and the impact of nanotechnology on society.
ÁñÁ«ÊÓƵ
THE MEDIA PROGRAMME
In addition to, and in parallel with, the general Conference programme, in which journalists are invited to participate, a dedicated press programme will be organised on 5-7 September. The press programme will include:
- Meniscus regeneration - a novel material composed of the patients' own cells on a fibrous matrix
to reconstruct the knee joint meniscus.
E. Tognana, Fidia Advanced Biopolymers, s.r.l. (I) - Cornea engineering - three dimensional reconstruction of the human cornea by tissue engineering
D.J.S. Hulmes, Institut de Biologie et Chimie des Protéines CNRS 7 (F) - Cellprom - cell programming by nanoscaled devices
Günter R. Fuhr, Institutsleiter Fraunhofer-Institut fürBiomedizinische Technik (D) - Nanosafe2: risk management strategies in nanotechnologies
M. Kayser, BASF Aktiengesellschaft (D) - Nano2life: Network of Excellence supporting interdisciplinary research into nanobiotechnology tools
and techniques
Patrick Boisseau, CEA-Léti (F) - Delivering cancer killing drugs through nanotechnologies
Andreas Jordan, CEO, MagForce Nanotechnologies GmbH (D)
For additional information on this press briefing, please contact:
Patrick Vittet-Philippe
Press
and Information Officer
DG Research, European Commission
Tel: +32.2.296.9056 – Mobile:
+32.477.4.663.
E-mail: patrick.vittet-philippe@cec.eu.int
Further information:
DG Research
ndex_en.html
Item source: /2005/pr1907-2en.cfm
Previous Item
Back to Titles
ÁñÁ«ÊÓƵ
Register to continue
Why register?
- Registration is free and only takes a moment
- Once registered, you can read 3 articles a month
- Sign up for our newsletter
Subscribe
Or subscribe for unlimited access to:
- Unlimited access to news, views, insights & reviews
- Digital editions
- Digital access to °Õ±á·¡¡¯²õ university and college rankings analysis
Already registered or a current subscriber? Login